Gallagher J, Russell L, McAlister M, Brockbank J. Impact of gemtuzumab ozogamicin on the Irish healthcare system. Poster presented at the ISPOR 2019 European Conference; November 4, 2019. Copenhagen, Denmark. [abstract] Value Health. 2019 Dec; 22(S3).
Basarir H, Brockbank J, Knight C, Wolowacz S. The inclusion of the utility values for carers and family members in HTAs: a case study of recent NICE appraisals in the UK. Poster presented at the 2019 ISPOR 24th Annual International Meeting; May 22, 2019. New Orleans, LA. [abstract] Value in Health Regional Issues. 2019 May; 22(Suppl 2):S330.
Mokgokong R, Mamolo C, Cappelleri J, Knight C, Brockbank J, Cawson M, Dombre H, Castaigne S. Cost-effectiveness of gemtuzumab ozogamicin in combination with standard of care chemotherapy (daunorubicin and cytarabine) for first-line treatment of acute myeloid leukaemia. Poster presented at the 2019 British Society for Haematology Meeting; April 1, 2019. Glasgow, Scotland.
Pearson IV, Wolowacz SE, Irving AH, Brockbank JA, Chubb B, Gundgaard J, Briggs A, Davies M. A systematic review of recent data describing the risk of complications in type 1 diabetes mellitus patients. Poster presented at the 2012 ISPOR 15th Annual European Congress; November 9, 2012. Berlin, Germany. [abstract] Value Health. 2012 Nov; 15(7):A496-7.